HVTN 108
Status:Completed
Phase:I/II
Principal Investigator(s):Nigel Garrett
Objective:This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.
Last updated March 24, 2021
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
DescriptionGroup 1: DNA-HIV-PT123 + Placebo + Protein/MF59
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionGroup 2: DNA-HIV-PT123 + Placebo + Protein/AS01B
Mode of DeliveryIntermuscular
ARMsExperimental
DescriptionGroup 3: DNA-HIV-PT123 + Placebo + Protein/AS01B
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionGroup 4: DNA-HIV-PT123 + Placebo + Protein/MF59
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code:
NCT02915016
Trial Sponsors:
NIAID (DAIDS-ES: 12007)
Start Date
End Date
December 1, 2016
February 12, 2020
Enrollment:334
Age range:
18 Years ↔
40 Years
Population:Cisgender Men, Cisgender Women